volume 37, issue 6, P548-558 2017
DOI: 10.1007/s10875-017-0422-6
View full text
|
|
Share

Abstract: A reduced-intensity allogeneic transplant protocol based on alemtuzumab and busulfan with sirolimus GVHD prophylaxis produced high rates of successful engraftment and minimal regimen-related toxicity. Prolonged clinical follow-up has confirmed its efficacy in ameliorating CGD-related disease. Outcomes were not acceptable with donor cell infusion rescue of cause with poor graft function.

Search citation statements

Order By: Relevance

Paper Sections

0
0
0
0
0

Citation Types

0
22
0
1

Publication Types

Select...

Relationship

0
0

Authors

Journals